These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36535666)

  • 1. Impact of Digital Technologies on Clinical Care for Adults with Cystic Fibrosis.
    Peckham D; Spoletini G
    Semin Respir Crit Care Med; 2023 Apr; 44(2):217-224. PubMed ID: 36535666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infection control in cystic fibrosis: evolving perspectives and challenges.
    Jones AM
    Curr Opin Pulm Med; 2022 Nov; 28(6):571-576. PubMed ID: 36101908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    O'Carroll M
    Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of digital health in adults with cystic fibrosis.
    Carnovale V; Iacotucci P; Qiao D; Ferrillo L; Somma J; Buonaurio S; Marcella d'Ippolito ; Celardo A; Savi D
    Respir Med; 2022 Oct; 202():106970. PubMed ID: 36058164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of cystic fibrosis care: a global perspective.
    Bell SC; Mall MA; Gutierrez H; Macek M; Madge S; Davies JC; Burgel PR; Tullis E; Castaños C; Castellani C; Byrnes CA; Cathcart F; Chotirmall SH; Cosgriff R; Eichler I; Fajac I; Goss CH; Drevinek P; Farrell PM; Gravelle AM; Havermans T; Mayer-Hamblett N; Kashirskaya N; Kerem E; Mathew JL; McKone EF; Naehrlich L; Nasr SZ; Oates GR; O'Neill C; Pypops U; Raraigh KS; Rowe SM; Southern KW; Sivam S; Stephenson AL; Zampoli M; Ratjen F
    Lancet Respir Med; 2020 Jan; 8(1):65-124. PubMed ID: 31570318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Diversity and Instability of the Sinus Microbiota over Time in Adults with Cystic Fibrosis.
    Armbruster CR; Li K; Kiedrowski MR; Zemke AC; Melvin JA; Moore J; Atteih S; Fitch AC; DuPont M; Manko CD; Weaver ML; Gaston JR; Alcorn JF; Morris A; Methé BA; Lee SE; Bomberger JM
    Microbiol Spectr; 2022 Oct; 10(5):e0125122. PubMed ID: 36094193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis.
    Ramsey ML; Gokun Y; Sobotka LA; Wellner MR; Porter K; Kirkby SE; Li SS; Papachristou GI; Krishna SG; Stanich PP; Hart PA; Conwell DL; Lara LF
    Am J Gastroenterol; 2021 Dec; 116(12):2446-2454. PubMed ID: 34665155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy.
    Lehr CJ; Pilewski JM
    Curr Opin Organ Transplant; 2022 Jun; 27(3):198-203. PubMed ID: 35184094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing landscape: psychological care in the era of cystic fibrosis transmembrane conductance regulator modulators.
    Havermans T; Duff AJA
    Curr Opin Pulm Med; 2020 Nov; 26(6):696-701. PubMed ID: 32941351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis.
    Karb DB; Cummings LC
    Curr Gastroenterol Rep; 2021 Aug; 23(10):17. PubMed ID: 34448955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy.
    Lahiri T; Sullivan JS
    Pediatr Pulmonol; 2022 Feb; 57 Suppl 1():S60-S74. PubMed ID: 34473419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy.
    Farley H; Poole S; Chapman S; Flight W
    Postgrad Med J; 2022 May; 98(1159):341-345. PubMed ID: 33452147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of highly effective CFTR modulator therapy on digital clubbing in patients with cystic fibrosis.
    Mahlen T; Barton L; Roberts D
    J Cyst Fibros; 2022 Sep; 21(5):861-865. PubMed ID: 35915048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies.
    Desai M; Hine C; Whitehouse JL; Brownlee K; Charman SC; Nagakumar P
    Respir Med; 2022 Aug; 199():106878. PubMed ID: 35633605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy.
    Saiman L
    Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S18-S26. PubMed ID: 31715086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators.
    George A; Smith B; Sawicki GS; Goetz DM
    Pediatr Pulmonol; 2020 Nov; 55(11):2983-2989. PubMed ID: 32589808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
    Lommatzsch ST; Taylor-Cousar JL
    Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
    Smith S; Borchardt M
    J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.